Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program
Decision brief
Answer first · skim in under a minute
Medicus Pharma Ltd. is set to present at Biotech Showcase 2026, highlighting the upcoming readout of its Phase 2 SkinJect clinical data. This presentation underscores the company's strategic focus on advancing select programs through proof-of-concept and pursuing strategic partnerships.
Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program is a partnering-stage update, not an approval. The January 5, 2026 GlobeNewswire release ties the San Francisco showcase slot to completed Phase 2 SKNJCT-003 enrollment for SkinJect in basal cell carcinoma and planned FDA end-of-Phase 2 timing.
Contents9 sections
Key Takeaways
- Medicus Pharma (NASDAQ: MDCX) announced on January 5, 2026, that it will present at Biotech Showcase 2026 (January 12–14, 2026, San Francisco).
- SkinJect is a doxorubicin-containing dissolvable microneedle array (D-MNA) designed for non-invasive treatment of basal cell carcinoma (BCC).
- In December 2025, Medicus completed enrollment of 90 patients in Phase 2 SKNJCT-003 across nine U.S. clinical sites.
- The company expected SKNJCT-003 topline in Q1 2026 and an end-of-Phase 2 FDA meeting in the first half of 2026 — plans, not completed approvals.
What is Medicus highlighting at Biotech Showcase 2026?
Medicus said Dr. Raza Bokhari, Executive Chairman and CEO, will present clinical and partnering progress for SkinJect. Biotech Showcase is a partnering conference held alongside the J.P. Morgan Healthcare Conference week; attendance itself is not a regulatory milestone. The diligence value is whether management updates enrollment, readout timing, Gorlin Syndrome expanded-access plans, and business-development readiness with consistent numbers.
Primary announcement: January 5, 2026 GlobeNewswire Biotech Showcase release.
What is the SkinJect Phase 2 design?
SKNJCT-003 is described as a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept study evaluating safety, tolerability, and clinical efficacy of SkinJect D-MNA in BCC. Medicus reported completion of 90-patient U.S. enrollment in December 2025 across nine sites. Later 2026 company releases discussed topline and expanded datasets, including clinical and histological clearance figures in the 200-µg cohort — those post-showcase updates should be tracked separately from the January partnering announcement.
For registry-style confirmation, teams should also check ClinicalTrials.gov for the SKNJCT-003 listing and any protocol amendments before modeling registrational sample size.
Follow-on dataset context: March 9, 2026 GlobeNewswire Phase 2 dataset interpretation.
How does Gorlin Syndrome fit the partnering story?
Medicus has described collaboration with the Gorlin Syndrome Alliance to support access pathways for patients with multiple or inoperable BCCs using investigational D-MNA under physician supervision concepts such as Expanded Access IND planning. That is a rare-disease access and development wedge adjacent to sporadic BCC, not a second approved indication.
Investors should separate: (1) sporadic BCC Phase 2 signal, (2) end-of-Phase 2 FDA dialogue, and (3) Gorlin access programs. Only FDA labeling creates an approved indication.
Data points from the January 2026 announcement
- Ticker: NASDAQ: MDCX
- Showcase dates: January 12–14, 2026
- Phase 2 enrollment: 90 patients
- U.S. sites: nine
- Planned EOP2 FDA meeting window: H1 2026 (company expectation)
What remains unproven
As of the Biotech Showcase announcement, SkinJect was not FDA-approved. Histologic clearance rates, durability beyond early timepoints, and registrational endpoints remain subject to FDA feedback. Do not invent partnering deal values from a conference slot.
Related NovaPharma coverage
Frequently Asked Questions
When is Medicus presenting at Biotech Showcase 2026?
Medicus Pharma said it will present at Biotech Showcase 2026, taking place January 12–14, 2026, in San Francisco, with Executive Chairman and CEO Dr. Raza Bokhari delivering the company update.
What is SkinJect and how large is SKNJCT-003?
SkinJect is Medicus's doxorubicin-containing dissolvable microneedle array for basal cell carcinoma. SKNJCT-003 completed enrollment of 90 patients across nine U.S. sites as a randomized, double-blind, placebo-controlled Phase 2 study.
Has SkinJect been FDA approved?
No. As of the January 5, 2026 announcement, Medicus expected topline SKNJCT-003 results in the first quarter of 2026 and an end-of-Phase 2 FDA meeting in the first half of 2026.
Primary Sources
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
